How Do Advancements in Lung Cancer Immunotherapy Help Patients?
Immunotherapy is basically a cancer treatment that uses the body's immune system to fight cancer cells. You must be familiar with the traditional cancer treatments. It kills not just cancer cells but also healthy cells. That is why you often find severe side effects. And here comes the significance of immunotherapy.
Immunotherapy helps unmask cancer cells. So it becomes easier for our immune cells to find and attack cancer cells directly. This approach will help spare the healthy cells. So obviously, side effects will be less. This breakthrough approach has made cancer treatment more personalized. It gives people living with lung cancer new hope and promise.
What Are the Immunotherapy Approaches for Lung Cancer?
There are various immunotherapy methods for treating lung cancer. Each method has a different mechanism and function.
These methods consist of:
1. Immune Checkpoint Inhibitors:
A class of medication known as immune checkpoint inhibitors (ICIs) targets specific proteins on the surfaces of immune cells and cancer cells. They block the signals that prevent the immune system from responding to malignancy.
Lung cancer immunotherapy frequently uses:
-
PD-1 (programmed cell death protein 1) inhibitors.
-
PD-L1 (programmed death-ligand 1) inhibitors.
These medications have shown significant success, particularly in non-small cell lung cancer (NSCLC). They may result in more lasting reactions and higher survival rates.
2. Therapy using CAR-T Cells:
Chimeric antigen receptor T-cell therapy (CAR-T) is an advanced cancer treatment.
In this treatment, your doctor first collects your T cells. Then, modify the collected T cells in labs. This process is called genetic re-engineering. The re-engineering is designed so that the cells become more capable of recognizing and attacking cancer cells. The modified T cells are then reintroduced into your body. So far, CAT-T cell therapy has primarily been used for the treatment of blood cancers. However, it is being investigated for solid tumors, including lung cancer.
3. Adjuvant and Neoadjuvant Therapies:
To enhance outcomes for patients with early-stage lung cancer, immunotherapy is being investigated in the adjuvant (post-surgery) and neoadjuvant (pre-surgery) settings. As an adjuvant therapy, it can minimize your cancer recurrence. While in neoadjuvant therapy, it helps reduce the cancer size.
4. Understanding Resistance Processes:
Over time, you may find that immunotherapy is not giving the results it used to. Researchers are now working on this to better understand why it happens. They are investigating the tumor microenvironment, the function of immunosuppressive cells, and other components of this. A proper understanding of this process will help them develop measures to overcome the resistance.
5. Rare Subtypes and Small Cell Lung Cancer:
Immunotherapy options for rare subtypes of lung cancer and SCLC have been limited. However, ongoing research aims to enhance treatment options in these fields.
6. Vaccines:
Therapeutic cancer vaccines activate the immune system to identify and combat cancer cells.
The possibility of DNA (deoxyribonucleic acid) and peptide-based vaccines for lung cancer immunotherapy is also being studied. These vaccinations can target specific tumor antigens.
7. Cytokine Treatment:
Examples of cytokine therapies that activate the immune system's reaction against cancer cells include interferon and interleukin-based therapy. Due to their drawbacks and ineffectiveness, these methods are less frequently used.
8. Oncolytic Viruses:
-
Oncolytic viruses are specially crafted viruses that target and destroy cancer cells while activating the immune system.
-
Oncolytic viruses are currently the subject of clinical trials to determine their potential as lung cancer treatments.
9. Integrative Therapies:
-
Combinations of immunotherapies with other therapies, such as targeted therapies or chemotherapy, are being investigated to improve treatment efficacy and combat resistance.
-
For instance, using ICIs in combination with chemotherapy in NSCLC has occasionally yielded positive outcomes.
What Are the Benefits of Immunotherapy in Lung Cancer?
1. Increased Survival Rates:
Patients with lung cancer have been demonstrated to live longer while receiving immunotherapy. This is mainly observed when their disease is advanced, and conventional therapies like chemotherapy may be ineffective. When compared to chemotherapy, checkpoint inhibitors have been shown to enhance overall survival significantly.
2. Targeting Tumor-Specific Proteins:
Immunotherapy medications function by specifically targeting proteins on the surface of immune or cancer cells. For instance, PD-1 and PD-L1 inhibitors focus on the PD-1/PD-L1 pathway. It is these pathways that cancer cells use to trick the immune system into thinking they are not there. By targeting cancer cells, this focused strategy helps protect healthy cells from the damaging effects of chemotherapy. So the side effects are fewer.
3. Fewer Side Effects:
Immunotherapy generally has less severe side effects than conventional therapies like chemotherapy. Traditional treatments can damage cancer cells, healthy cells, and tissues, resulting in disabling side effects. The side effects of immunotherapy are quite milder and more tolerable. Fatigue, rash, and diarrhea are common.
4. Personalized Treatment:
Immunotherapy can be tailored to the individual patient's tumor characteristics. Tests like PD-L1 expression and tumor mutational burden (TMB) can help identify patients more likely to respond to immunotherapy. This allows for a more personalized treatment approach.
5. Long-lasting Responses:
Immunotherapy occasionally produces lasting responses. During this period, your immune system attacks and controls the malignancy. This is incredibly hopeful for lung cancer patients with progressed or metastatic disease.
Conclusion:
The field of lung cancer therapy has been revolutionized because of immunotherapy. It gave new hope to those fighting against lung cancer. Advancements in immunotherapy led to new treatment strategies. However, patients often have doubts about whether immunotherapy is a better fit than traditional chemotherapy.
Immune checkpoint inhibitors, customized therapies, and novel combination therapies are the major advancements. These developments have increased patient survival rates and greatly enhanced their quality of life. Better treatment outcomes with minimal side effects are the most attractive aspect of immunotherapy. Consult with our oncologist, who can provide you with more information and handle your concerns with care.
Key Takeaways:
-
Immunotherapy helps our body identify and destroy lung cancer cells.
-
Though most patients show better results, over time, some may develop resistance.
-
Lasting results and fewer side effects are the most impressive aspects of immunotherapy.
-
Newer immunotherapy approaches, such as CAR-T therapy, are being studied for lung cancer treatment.
